Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 217

1.

Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?

Capusan TM, Herrero-Moyano M, Martínez-Mera CR, Freih-Fraih AW, Dauden E.

JAAD Case Rep. 2018 Jun 2;4(6):521-523. doi: 10.1016/j.jdcr.2018.04.015. eCollection 2018 Jul. No abstract available.

2.

Position Statement for the Management of Comorbidities in Psoriasis.

Dauden E, Blasco AJ, Bonanad C, Botella R, Carrascosa JM, González-Parra E, Jodar E, Joven B, Lázaro P, Olveira A, Quintero J, Rivera R.

J Eur Acad Dermatol Venereol. 2018 Jul 10. doi: 10.1111/jdv.15177. [Epub ahead of print]

PMID:
29992631
3.

Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient.

Rodríguez-Jiménez P, Mir-Viladrich I, Chicharro P, Solano-López G, López-Longo FJ, Taxonera C, Sánchez-Martínez P, Martínez-Lacasa X, García-Gasalla M, Dorca J, Arias-Guillén M, García-García JM, Dauden E.

Actas Dermosifiliogr. 2018 Jun 2. pii: S0001-7310(18)30179-0. doi: 10.1016/j.ad.2018.03.013. [Epub ahead of print] English, Spanish.

PMID:
29871738
4.

Facial Calcinosis Cutis in a Woman with Paraneoplastic Dermatomyositis.

Herrero-Moyano M, Martínez-Mera C, García-García C, Dauden E.

Actas Dermosifiliogr. 2018 Mar 26. pii: S0001-7310(17)30612-9. doi: 10.1016/j.ad.2017.11.004. [Epub ahead of print] English, Spanish. No abstract available.

PMID:
29598989
5.

GATA3 staining in primary cutaneous apocrine cribriform carcinoma: Usefulness to differentiate it from breast cancer metastasis.

Llamas-Velasco M, Pérez-Gónzalez YC, Daudén E, Rütten A.

J Cutan Pathol. 2018 May;45(5):348-351. doi: 10.1111/cup.13124. Epub 2018 Mar 12.

PMID:
29431200
6.

Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study.

Chicharro P, Paniagua A, Rodríguez-Jiménez P, Ibañes S, Cortina B, Riveiro J, Sampedro-Núñez MÁ, Fraga J, Marazuela M, Daudén E.

J Eur Acad Dermatol Venereol. 2018 Jan 29. doi: 10.1111/jdv.14830. [Epub ahead of print]

PMID:
29377286
7.

Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.

Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Talegón M, Cabaleiro T, Daudén E, Abad-Santos F.

Pharmacogenomics. 2018 Jan;19(1):7-16. doi: 10.2217/pgs-2017-0143. Epub 2017 Dec 1.

PMID:
29192552
8.

Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study.

Descalzo MA, Carretero G, Ferrándiz C, Rivera R, Daudén E, Gómez-García FJ, de la Cueva P, Herrera-Ceballos E, Belinchón I, López-Estebaranz JL, Alsina M, Sánchez-Carazo JL, Ferrán M, Baniandrés O, Carrascosa JM, Llamas-Velasco M, Ruiz-Genao D, Herrera-Acosta E, Muñoz-Santos C, García-Doval I; Biobadaderm Study Group.

J Am Acad Dermatol. 2018 Apr;78(4):798-800. doi: 10.1016/j.jaad.2017.10.051. Epub 2017 Nov 13. No abstract available.

PMID:
29146129
9.

Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.

Ovejero-Benito MC, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Abad-Santos F, Daudén E.

Am J Clin Dermatol. 2018 Apr;19(2):209-222. doi: 10.1007/s40257-017-0322-9. Review.

PMID:
28921458
10.

European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.

Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, Saiag P, Smith CH, Dauden E, de Jong EM, Feist E, Jobling R, Maccarone M, Mrowietz U, Papp KA, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Dressler C.

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1951-1963. doi: 10.1111/jdv.14454. Epub 2017 Sep 11. No abstract available.

PMID:
28895202
11.

Recommendations for the management of comorbidity in hidradenitis suppurativa.

Dauden E, Lazaro P, Aguilar MD, Blasco AJ, Suarez C, Marin I, Queiro R, Bassas-Vila J, Martorell A, García-Campayo J.

J Eur Acad Dermatol Venereol. 2018 Jan;32(1):129-144. doi: 10.1111/jdv.14517. Epub 2017 Sep 12.

PMID:
28796920
12.

Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease.

Bonanad C, González-Parra E, Rivera R, Carrascosa JM, Daudén E, Olveira A, Botella-Estrada R.

Actas Dermosifiliogr. 2017 Nov;108(9):800-808. doi: 10.1016/j.ad.2016.12.023. Epub 2017 Jun 11. Review. English, Spanish.

PMID:
28610662
13.

No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.

Rodríguez-Jiménez P, Chicharro P, Godoy A, Llamas-Velasco M, García M, Daudén E.

Br J Dermatol. 2017 Sep;177(3):862-863. doi: 10.1111/bjd.15654. Epub 2017 Jul 19. No abstract available.

PMID:
28508387
14.

Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.

Belinchón I, Ramos JM, Carretero G, Ferrándiz C, Rivera R, Daudén E, De la Cueva-Dobao P, Gómez-García FJ, Herrera-Ceballos E, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Llamas-Velasco M, Ortiz PL, García-Doval I, Descalzo MA; Biobadaderm Study Group.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1700-1708. doi: 10.1111/jdv.14314. Epub 2017 Jun 6.

PMID:
28485816
15.

Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis.

Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Belmonte C, Cabaleiro T, Román M, Ochoa D, Talegón M, Saiz-Rodríguez M, Daudén E, Abad-Santos F.

Pharmacogenomics. 2017 May;18(7):631-638. doi: 10.2217/pgs-2017-0014. Epub 2017 May 4.

PMID:
28470127
16.

Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.

Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, Thaci D.

J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1271-1284. doi: 10.1111/jdv.14277. Epub 2017 May 22. Review.

PMID:
28419600
17.

Treatment of Human Scabies with Oral Ivermectin. Eczematous Eruptions as a New Non-Reported Adverse Event.

Sanz-Navarro J, Feal C, Dauden E.

Actas Dermosifiliogr. 2017 Sep;108(7):643-649. doi: 10.1016/j.ad.2017.02.011. Epub 2017 Apr 3. English, Spanish.

PMID:
28385424
18.

Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis.

Ovejero-Benito MC, Cabaleiro T, Sanz-García A, Llamas-Velasco M, Saiz-Rodríguez M, Prieto-Pérez R, Talegón M, Román M, Ochoa D, Reolid A, Daudén E, Abad-Santos F.

Br J Dermatol. 2018 Mar;178(3):798-800. doi: 10.1111/bjd.15504. Epub 2018 Jan 28. No abstract available.

PMID:
28369750
19.

Psoriasis and Nonalcoholic Fatty Liver Disease.

Carrascosa JM, Bonanad C, Dauden E, Botella R, Olveira-Martín A; en nombre del Grupo de Trabajo en Inflamación Sistémica en Psoriasis.

Actas Dermosifiliogr. 2017 Jul - Aug;108(6):506-514. doi: 10.1016/j.ad.2016.12.017. Epub 2017 Mar 16. Review. English, Spanish.

PMID:
28318525
20.

Induction of Autoantibodies and Autoimmune Diseases in Patients with Psoriasis Receiving Tumor Necrosis Factor Inhibitors.

Oter-López B, Llamas-Velasco M, Sánchez-Pérez J, Dauden E.

Actas Dermosifiliogr. 2017 Jun;108(5):445-456. doi: 10.1016/j.ad.2016.12.014. Epub 2017 Mar 6. English, Spanish.

PMID:
28267955

Supplemental Content

Loading ...
Support Center